Pharma & Biotech
Outlook Therapeutics Clears Nasdaq Hurdle but Faces $39M Debt and FDA Deadline
Outlook Therapeutics has escaped the threat of expulsion from the Nasdaq Capital Market, but the relief is tempered by a...
BioNTech Rolls Out a $1 Billion Buyback While Racing Toward Its First Cancer Approval
BioNTech is simultaneously tightening its belt and opening its wallet, a dual move that signals both caution and ambition as...
Canopy Growth Gets a Shot in the Arm From Both Washington and Its Own Books
Canopy Growth shareholders have had little to cheer about this year, but the past few days delivered two distinct catalysts...
Ocugen’s Insider and Institutional Conviction Rises as a Dense Timeline of Gene Therapy Catalysts Approaches
Ocugen enters a make-or-break stretch that will test both its science and its stock. The gene therapy developer, which has...
Bayer’s Supreme Court Victory Reshapes the Legal Landscape — But the July 9 Hearing Will Test Whether the Rally Can Hold
The U.S. Supreme Court handed Bayer a landmark win on June 25, effectively closing the most potent legal avenue for...
Novo Nordisk Faces a Demand Flood as Production Race Nears Critical Juncture
A pair of catalysts is converging on Novo Nordisk just as the Danish drugmaker scrambles to expand its manufacturing footprint....
Bayer’s Two-Front Offensive: Legal Closure Paves the Way for a Pipeline-Fueled Rebound
The Supreme Court’s 7–2 ruling excising thousands of Roundup claims from Bayer’s docket was the kind of event that sends...
Novo Nordisk’s Share Recovery Picks Up as Legal, Pipeline, and Pill Catalysts Converge
Novo Nordisk’s stock has clawed back more than a third of its losses since the March 2026 trough, closing at...
Bayer Juggles a $2.45 Billion Biotech Bet and a Washington Trade Probe
Bayer’s stock crept back above a closely watched technical threshold on Friday, but the real drama for the German healthcare...
Ocugen’s CFO Bets on Her Own Stock as a Packed Conference Schedule Previews a Pivotal Summer
The clinical calendar is tightening for Ocugen, and the stock is starting to stir in anticipation. Shares closed the week...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
